Form D · Biotechnology
CELESTIAL THERAPEUTICS INC.
Irvine, CA · CIK 0001804448
Offering snapshot reported Jul 6, 2026 · SEC filing
- Reported sold
- $850K Indefinite offering
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $20K Reported outside-investor minimum
- First sale
- Sep 3, 2024 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$800,000 → $850,000
- Reported investors10 → 11
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 6, 2026 | Amendment | $850,000 | $50,000vs Oct 9, 2025 | 11 | SEC filing |
| Oct 9, 2025 | Amendment | $800,000 | $25,000vs Jun 23, 2025 | 10 | SEC filing |
| Jun 23, 2025 | Amendment | $775,000 | $50,000vs May 21, 2025 | 9 | SEC filing |
| May 21, 2025 | Amendment | $725,000 | $100,000vs May 8, 2025 | 8 | SEC filing |
| May 8, 2025 | Amendment | $625,000 | $50,000vs Apr 25, 2025 | 8 | SEC filing |
| Apr 25, 2025 | Amendment | $575,000 | $25,000vs Apr 7, 2025 | 7 | SEC filing |
| Apr 7, 2025 | Amendment | $550,000 | $50,000vs Mar 27, 2025 | 6 | SEC filing |
| Mar 27, 2025 | Amendment | $500,000 | $100,000vs Feb 13, 2025 | 5 | SEC filing |
| Feb 13, 2025 | Amendment | $400,000 | $100,000vs Jan 23, 2025 | 4 | SEC filing |
| Jan 23, 2025 | Amendment | $300,000 | $200,000vs Sep 10, 2024 | 3 | SEC filing |
| Sep 10, 2024 | Initial | $100,000 | No comparison | 1 | SEC filing |
| Apr 11, 2024 | Amendment | $1,339,224 | $109,224vs Mar 21, 2024 | 13 | SEC filing |
| Mar 21, 2024 | Amendment | $1,230,000 | $100,000vs Jun 23, 2023 | 12 | SEC filing |
| Jun 23, 2023 | Amendment | $1,130,000 | $45,000vs Jun 1, 2023 | 12 | SEC filing |
| Jun 1, 2023 | Amendment | $1,085,000 | $50,000vs May 5, 2023 | 11 | SEC filing |
| May 5, 2023 | Amendment | $1,035,000 | $25,000vs Apr 24, 2023 | 11 | SEC filing |
| Apr 24, 2023 | Amendment | $1,010,000 | $100,000vs Jul 28, 2022 | 11 | SEC filing |
| Jul 28, 2022 | Amendment | $910,000 | $20,000vs Jul 14, 2022 | 11 | SEC filing |
| Jul 14, 2022 | Amendment | $890,000 | $25,000vs Feb 10, 2022 | 11 | SEC filing |
| Feb 10, 2022 | Amendment | $865,000 | $185,000vs Jan 6, 2022 | 10 | SEC filing |
| Jan 6, 2022 | Amendment | $680,000 | $50,000vs Dec 22, 2021 | 9 | SEC filing |
| Dec 22, 2021 | Amendment | $630,000 | $50,000vs Sep 24, 2021 | 9 | SEC filing |
| Sep 24, 2021 | Amendment | $580,000 | $100,000vs Sep 3, 2021 | 9 | SEC filing |
| Sep 3, 2021 | Amendment | $480,000 | $50,000vs Mar 25, 2021 | 9 | SEC filing |
| Mar 25, 2021 | Amendment | $430,000 | $20,000vs Feb 18, 2021 | 9 | SEC filing |
| Feb 18, 2021 | Amendment | $410,000 | $100,000vs Jan 27, 2021 | 8 | SEC filing |
| Jan 27, 2021 | Amendment | $310,000 | $80,000vs Dec 17, 2020 | 7 | SEC filing |
| Dec 17, 2020 | Amendment | $230,000 | $20,000vs Sep 21, 2020 | 6 | SEC filing |
| Sep 21, 2020 | Amendment | $210,000 | $15,000vs Jul 31, 2020 | 6 | SEC filing |
| Jul 31, 2020 | Amendment | $195,000 | $60,000vs Jun 15, 2020 | 6 | SEC filing |
| Jun 15, 2020 | Amendment | $135,000 | $20,000vs Apr 17, 2020 | 5 | SEC filing |
| Apr 17, 2020 | Amendment | $115,000 | $90,000vs Apr 9, 2020 | 4 | SEC filing |
| Apr 9, 2020 | Initial | $25,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-523696
Total amount sold represents gross proceeds of sale of 850,000 common shares of the issuer at $1.00 per common share.
Source: Form D, filed Jul 6, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Annelise Barron | Director |
| John Fortkort | Executive |
| Ajay Gupta | Director, Executive |
| George Siber | Director |
| Leontis Teryazos | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:Irvine, CA, 92620
Phone: 9494022388